European Organisation for Research and Treatment of Cancer (EORTC)

Research / Science organisation


Location: Brüssel (Brussels), Belgium (BE) BE

ISNI: 0000000406100854

ROR: https://ror.org/034wxcc35

Show on Map:

close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Technical considerations for isolated limb perfusion: A consensus paper (2024) Hayes AJ, Coker DJ, Been L, Boecxstaens VW, Bonvalot S, De Cian F, de la Cruz-Merino L, et al. Journal article, Review article Long-term survival with IDH wildtype glioblastoma: first results from the ETERNITY Brain Tumor Funders’ Collaborative Consortium (EORTC 1419) (2023) Hertler C, Felsberg J, Gramatzki D, Le Rhun E, Clarke J, Soffietti R, Wick W, et al. Journal article Twenty Years On: RECIST as a Biomarker of Response in Solid Tumours an EORTC Imaging Group – ESOI Joint Paper (2022) Fournier L, de Geus-Oei LF, Regge D, Oprea-Lager DE, D’Anastasi M, Bidaut L, Bäuerle T, et al. Journal article, Review article Bone Metastases Are Measurable: The Role of Whole-Body MRI and Positron Emission Tomography (2021) Oprea-Lager DE, Cysouw MC, Boellaard R, Deroose CM, de Geus-Oei LF, Lopci E, Bidaut L, et al. Journal article, Review article Development of randomized trials in adults with medulloblastoma—the example of eortc 1634-btg/noa-23 (2021) Hau P, Frappaz D, Hovey E, Mccabe MG, Pajtler KW, Wiestler B, Seidel C, et al. Journal article Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. (2021) Bottomley A, Coens C, Mierzynska J, Blank CU, Mandalà M, Long GV, Atkinson VG, et al. Journal article Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. (2021) Eggermont AM, Blank CU, Mandalà M, Long GV, Atkinson VG, Dalle S, Haydon AM, et al. Journal article Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials (2021) Burdett S, Fisher DJ, Vale CL, Bono AV, Clarke NW, Cognetti F, Collette L, et al. Journal article, Review article Prognosis of Patients With Stage III Melanoma According to American Joint Committee on Cancer Version 8: A Reassessment on the Basis of 3 Independent Stage III Melanoma Cohorts (2020) Garbe C, Keim U, Suciu S, Amaral T, Eigentler TK, Gesierich A, Hauschild A, et al. Journal article Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, Treat CTC): a randomized phase II trial (2018) Ignatiadis M, Litiere S, Rothe F, Riethdorf S, Proudhon C, Fehma T, Aalders K, et al. Journal article
‹ 1 2 ›